Mirati Therapeutics (MRTX) Stock Forecast, Price & News

Mirati Therapeutics (NASDAQ:MRTX) Frequently Asked Questions

Is Mirati Therapeutics a buy right now?

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Mirati Therapeutics in the last year. There are currently 3 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Mirati Therapeutics stock.
View analyst ratings for Mirati Therapeutics or view top-rated stocks.

When is Mirati Therapeutics' next earnings date?

Mirati Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Mirati Therapeutics.

How were Mirati Therapeutics' earnings last quarter?

Mirati Therapeutics, Inc. (NASDAQ:MRTX) announced its quarterly earnings data on Wednesday, May, 4th. The biotechnology company reported ($3.40) earnings per share for the quarter, missing the consensus estimate of ($3.37) by $0.03. The biotechnology company earned $0.71 million during the quarter, compared to analysts' expectations of $0.18 million. The firm's revenue for the quarter was up 6990.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($2.67) EPS.
View Mirati Therapeutics' earnings history.

What price target have analysts set for MRTX?

12 analysts have issued 12-month price targets for Mirati Therapeutics' shares. Their forecasts range from $115.00 to $247.00. On average, they anticipate Mirati Therapeutics' stock price to reach $172.58 in the next twelve months. This suggests a possible upside of 193.5% from the stock's current price.
View analysts' price targets for Mirati Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Mirati Therapeutics' key executives?

Mirati Therapeutics' management team includes the following people:

• Mr. David D. Meek, CEO & Director (Age 59, Pay $974.53k)
• Dr. Charles M. Baum M.D., Ph.D., Founder, Pres, Head of R&D and Director (Age 64, Pay $1.11M) (LinkedIn Profile)
• Ms. Vickie W. Reed, Sr. VP & Chief Accounting Officer (Age 60, Pay $570.7k) (LinkedIn Profile)
• Dr. James G. Christensen Ph.D., Chief Scientific Officer (Age 54, Pay $784.42k)
• Mr. Benjamin J. Hickey M.B.A., Chief Commercial Officer (Age 47, Pay $769.03k) (LinkedIn Profile)
• Ms. Reena R. Desai, Chief Legal Officer & Corp. Sec.
• Ms. Kristin Gustafson, Chief HR Officer
• Dr. Kelly Covello Ph.D., VP & Head of Medical Affairs
• Mr. Ryan Asay, VP & Head of Corp. Affairs

Who are some of Mirati Therapeutics' key competitors?

Some companies that are related to Mirati Therapeutics include BeiGene (BGNE), Elanco Animal Health (ELAN), Biohaven Pharmaceutical (BHVN), United Therapeutics (UTHR), Organon & Co. (OGN), Dr. Reddy's Laboratories (RDY), Teva Pharmaceutical Industries (TEVA), Grifols (GRFS), Jazz Pharmaceuticals (JAZZ), Maravai LifeSciences (MRVI), Sarepta Therapeutics (SRPT), Legend Biotech (LEGN), Intra-Cellular Therapies (ITCI), Ionis Pharmaceuticals (IONS) and Acerus Pharmaceuticals (ASPCF).
View all of MRTX's competitors.

What other stocks do shareholders of Mirati Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mirati Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), AbbVie (ABBV), QUALCOMM (QCOM), BioMarin Pharmaceutical (BMRN), Micron Technology (MU), Netflix (NFLX), Square (SQ), Alibaba Group (BABA) and DocuSign (DOCU).

What is Mirati Therapeutics' stock symbol?

Mirati Therapeutics trades on the NASDAQ under the ticker symbol "MRTX."

Who are Mirati Therapeutics' major shareholders?

Mirati Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (8.07%), BlackRock Inc. (5.04%), Wellington Management Group LLP (4.47%), State Street Corp (2.56%), Artal Group S.A. (2.43%) and RA Capital Management L.P. (1.32%). Company insiders that own Mirati Therapeutics stock include Benjamin Hickey, Boxer Capital, Llc, Bruce L A Carter, Charles M Baum, Craig A Johnson, Daniel Faga, Henry J Fuchs, Jamie Christensen, Julie M Cherrington, Ltd Braslyn, Maria E Martinez and Vickie S Reed.
View institutional ownership trends for Mirati Therapeutics.

Which major investors are selling Mirati Therapeutics stock?

MRTX stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Lord Abbett & CO. LLC, Paradigm Biocapital Advisors LP, Goldman Sachs Group Inc., Neuberger Berman Group LLC, Artal Group S.A., First Trust Advisors LP, and Royal Bank of Canada. Company insiders that have sold Mirati Therapeutics company stock in the last year include Benjamin Hickey, Charles M Baum, Jamie Christensen, Julie M Cherrington, and Vickie S Reed.
View insider buying and selling activity for Mirati Therapeutics or view top insider-selling stocks.

Which major investors are buying Mirati Therapeutics stock?

MRTX stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, RA Capital Management L.P., Fiera Capital Corp, Bank of Montreal Can, Deerfield Management Company L.P. Series C, Eventide Asset Management LLC, Rock Springs Capital Management LP, and Suvretta Capital Management LLC.
View insider buying and selling activity for Mirati Therapeutics or or view top insider-buying stocks.

How do I buy shares of Mirati Therapeutics?

Shares of MRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Mirati Therapeutics' stock price today?

One share of MRTX stock can currently be purchased for approximately $58.80.

How much money does Mirati Therapeutics make?

Mirati Therapeutics has a market capitalization of $3.26 billion and generates $72.09 million in revenue each year. The biotechnology company earns $-581.78 million in net income (profit) each year or ($11.90) on an earnings per share basis.

How many employees does Mirati Therapeutics have?

Mirati Therapeutics employs 413 workers across the globe.

What is Mirati Therapeutics' official website?

The official website for Mirati Therapeutics is www.mirati.com.

How can I contact Mirati Therapeutics?

Mirati Therapeutics' mailing address is 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at (858) 332-3410 or via email at [email protected].